Palvella Therapeutics, Inc. (NASDAQ: PVLA)

Pieris Pharmaceuticals, Inc., often recognized by its stock symbol PIRS, is a biotechnology company that operates in the pharmaceutical industry. The company is known for its Anticalin protein-based drugs, which target validated disease pathways in unique and transformative ways. These drugs are derived from human proteins called lipocalins and can bind tightly and specifically to a diverse range of targets. Pieris Pharmaceuticals has developed proprietary Anticalin libraries through protein engineering expertise, allowing for the optimization of half-life and dosing schedules.

The company's main business activities revolve around the discovery and development of these Anticalin protein-based drugs. Pieris Pharmaceuticals operates primarily in the immuno-oncology (IO) sector, with a clinical pipeline consisting of IO bispecifics developed in partnership with major pharmaceutical and biotechnology companies like Servier, Pfizer, and Boston Pharmaceuticals.

Pieris Pharmaceuticals generates revenue through its Anticalin platform technology. The company's primary products and services include 4-1BB bispecific Mabcalin IO assets, which are developed in partnership with other industry leaders. Specifically, the company's partnered programs include S095012, a PD-L1/4-1BB bispecific Mabcalin compound currently in a phase 1/2 study, and SGN-BB228, a CD228/4-1BB bispecific antibody-Anticalin compound being advanced in the clinic by Pfizer. Additionally, the company's clinical pipeline includes BOS-342, a GPC3/4-1BB bispecific Mabcalin compound exclusively licensed to Boston Pharmaceuticals, and cinrebafusp alfa, a bispecific Mabcalin compound comprising a HER2-targeting antibody linked to 4-1BB-targeting Anticalin proteins.

In terms of its position within the industry, Pieris Pharmaceuticals' Anticalin platform technology offers several advantages over antibodies. These advantages include small size, biophysical stability, optimization of half-life, and flexible formatting that facilitates the selection of potent T cell engagers. The company believes its Anticalin technology can drive efficient activation of tumor-specific T cells in the vicinity of the tumor, thereby avoiding some of the toxicities observed with peripheral T cell activation in healthy tissues.

Notably, Pieris Pharmaceuticals does not own or operate any manufacturing facilities and relies on third-party contract manufacturing organizations (CMOs) for the manufacturing of its drug candidates. The company's intellectual property portfolio includes issued patents and pending patent applications related to its Anticalin technology, as well as trademarks in the United States and foreign jurisdictions. Additionally, Pieris Pharmaceuticals has entered into strategic partnerships and license agreements with major pharmaceutical and biotechnology companies, including Servier, Pfizer, and Boston Pharmaceuticals. These partnerships involve the development and screening of drug candidates, as well as in vitro potency and efficacy testing using the company's Anticalin-brand drug discovery platform, Anticalin libraries, and other proprietary methods.

The research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, sales, and other aspects of drug products are regulated by governmental authorities in the United States and other countries. Pieris Pharmaceuticals conducts clinical trials in accordance with Good Clinical Practices (GCP) and other applicable regulations, and the company's marketing application submissions are reviewed by the FDA, which determines whether the product candidate is safe and effective for its proposed indication or indications.